Seikagaku reported FY 2Q20 orthopedic revenue of USD $31.3 million, -21.5% vs. 3Q19. The company’s ARTZ viscosupplement continued to take market share in Japan, but decreases in outpatient procedures due to COVID and drug price reductions offset those gains. While elective procedure recovery continued in the U.S., stocking orders fell compared to the prior year. Seikagaku’s sales in China decreased as well, due to curtailment of outpatient services in some areas of the country.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
2Q20
2Q19
$ Chg
% Chg
Orthobiologics
$31.3
$39.9
($8.6)
(21.5%)
1H20
1H19
$ Chg
% Chg
Orthobiologics
$59.5
$75.7
($16.2)
(21.4%)
Geographic Sales
2Q20
2Q19
$ Chg
% Chg
Domestic (Japan)
$11.5
$15.9
($4.4)
(27.6%)
International
$19.8
$24.0
($4.2)
(17.5%)
Total
$31.3
$39.9
($8.6)
(21.5%)
1H20
1H19
$ Chg
% Chg
Domestic (Japan)
$28.0
$32.4
($4.4)
(13.5%)
International
$31.5
$43.3
($11.8)
(27.2%)
Total
$59.5
$75.7
($16.2)
(21.4%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Seikagaku reported FY 2Q20 orthopedic revenue of USD $31.3 million, -21.5% vs. 3Q19. The company’s ARTZ viscosupplement continued to take market share in Japan, but decreases in outpatient procedures due to COVID and drug price reductions offset those gains. While elective procedure recovery continued in the U.S., stocking orders fell...
Seikagaku reported FY 2Q20 orthopedic revenue of USD $31.3 million, -21.5% vs. 3Q19. The company’s ARTZ viscosupplement continued to take market share in Japan, but decreases in outpatient procedures due to COVID and drug price reductions offset those gains. While elective procedure recovery continued in the U.S., stocking orders fell compared to the prior year. Seikagaku’s sales in China decreased as well, due to curtailment of outpatient services in some areas of the country.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
2Q20
2Q19
$ Chg
% Chg
Orthobiologics
$31.3
$39.9
($8.6)
(21.5%)
1H20
1H19
$ Chg
% Chg
Orthobiologics
$59.5
$75.7
($16.2)
(21.4%)
Geographic Sales
2Q20
2Q19
$ Chg
% Chg
Domestic (Japan)
$11.5
$15.9
($4.4)
(27.6%)
International
$19.8
$24.0
($4.2)
(17.5%)
Total
$31.3
$39.9
($8.6)
(21.5%)
1H20
1H19
$ Chg
% Chg
Domestic (Japan)
$28.0
$32.4
($4.4)
(13.5%)
International
$31.5
$43.3
($11.8)
(27.2%)
Total
$59.5
$75.7
($16.2)
(21.4%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
